Paratek Pharmaceuticals Company Profile (NASDAQ:PRTK)

About Paratek Pharmaceuticals (NASDAQ:PRTK)

Paratek Pharmaceuticals logoParatek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections. Sarecycline is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Its other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class. These research stage programs include product candidates for multiple sclerosis, spinal muscular atrophy, systemic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:PRTK
  • CUSIP: 89354M10
  • Web: www.paratekpharma.com
Capitalization:
  • Market Cap: $552.45 million
  • Outstanding Shares: 27,485,000
Average Prices:
  • 50 Day Moving Avg: $21.89
  • 200 Day Moving Avg: $16.88
  • 52 Week Range: $9.80 - $25.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.72
  • P/E Growth: -0.02
Sales & Book Value:
  • Annual Revenue: $46,999.00
  • Price / Sales: 11,754.47
  • Book Value: $3.30 per share
  • Price / Book: 6.09
Profitability:
  • EBIDTA: ($103,850,000.00)
  • Return on Equity: -115.44%
  • Return on Assets: -75.45%
Debt:
  • Debt-to-Equity Ratio: 0.23%
  • Current Ratio: 5.86%
  • Quick Ratio: 5.86%
Misc:
  • Average Volume: 826,305 shs.
  • Beta: 1.34
  • Short Ratio: 2
 

Frequently Asked Questions for Paratek Pharmaceuticals (NASDAQ:PRTK)

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) issued its earnings results on Thursday, May, 4th. The company reported ($1.14) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.20) by $0.06. The firm had revenue of $0.02 million for the quarter. View Paratek Pharmaceuticals' Earnings History.

Where is Paratek Pharmaceuticals' stock going? Where will Paratek Pharmaceuticals' stock price be in 2017?

9 brokerages have issued twelve-month target prices for Paratek Pharmaceuticals' stock. Their forecasts range from $23.00 to $56.00. On average, they anticipate Paratek Pharmaceuticals' share price to reach $38.22 in the next year. View Analyst Ratings for Paratek Pharmaceuticals.

What are analysts saying about Paratek Pharmaceuticals stock?

Here are some recent quotes from research analysts about Paratek Pharmaceuticals stock:

  • 1. Cantor Fitzgerald analysts commented, "Announced this morning, PRTK has entered into a collaborative agreement with Zai Lab to develop, manufacture and commercialize omadacycline in." (4/24/2017)
  • 2. According to Zacks Investment Research, "Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. " (4/21/2017)
  • 3. Robert W. Baird analysts commented, "Though sarecycline is not a key driver, it provides a potential source of non-dilutive financing and further validates Paratek's ability to develop a once daily, well tolerated, tetracycline-derived antibiotic. Looking ahead, we expect continued momentum with focus on key upcoming data readouts from two Phase 3 studies of omadacycline in 2Q17, supporting filing in 1H18, and we reiterate our Outperform rating." (3/27/2017)

Who are some of Paratek Pharmaceuticals' key competitors?

Who owns Paratek Pharmaceuticals stock?

Paratek Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Omega Fund Management LLC (10.71%), FMR LLC (8.71%), Baupost Group LLC MA (7.44%), Tekla Capital Management LLC (3.14%), Vanguard Group Inc. (2.98%) and Aisling Capital LLC (1.99%). Company insiders that own Paratek Pharmaceuticals stock include Douglas W Pagan, Evan Loh, Fund Iv LP Omega, Hbm Healthcare Investments (Ca and Michael Bigham. View Institutional Ownership Trends for Paratek Pharmaceuticals.

Who sold Paratek Pharmaceuticals stock? Who is selling Paratek Pharmaceuticals stock?

Paratek Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Granahan Investment Management Inc. MA, Granite Investment Partners LLC, United Services Automobile Association, JPMorgan Chase & Co., Stoneridge Investment Partners LLC, ProShare Advisors LLC and Nationwide Fund Advisors. Company insiders that have sold Paratek Pharmaceuticals stock in the last year include Douglas W Pagan, Evan Loh and Michael Bigham. View Insider Buying and Selling for Paratek Pharmaceuticals.

Who bought Paratek Pharmaceuticals stock? Who is buying Paratek Pharmaceuticals stock?

Paratek Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Royce & Associates LP, Candriam Luxembourg S.C.A., Morgan Stanley, C WorldWide Group Holding A S and Vanguard Group Inc.. Company insiders that have bought Paratek Pharmaceuticals stock in the last two years include Evan Loh, Fund Iv LP Omega and Michael Bigham. View Insider Buying and Selling for Paratek Pharmaceuticals.

How do I buy Paratek Pharmaceuticals stock?

Shares of Paratek Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Paratek Pharmaceuticals stock cost?

One share of Paratek Pharmaceuticals stock can currently be purchased for approximately $20.10.

Analyst Ratings

Consensus Ratings for Paratek Pharmaceuticals (NASDAQ:PRTK) (?)
Ratings Breakdown: 8 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.11)
Consensus Price Target: $38.22 (90.16% upside)

Analysts' Ratings History for Paratek Pharmaceuticals (NASDAQ:PRTK)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/18/2017Raymond James Financial, Inc.Initiated CoverageStrong-Buy -> Strong-Buy$36.00HighView Rating Details
5/4/2017Cantor FitzgeraldSet Price TargetBuy$33.00LowView Rating Details
4/11/2017HC WainwrightBoost Price TargetBuy -> Buy$33.00 -> $36.00LowView Rating Details
4/4/2017GuggenheimSet Price TargetBuy$38.00MediumView Rating Details
4/4/2017BTIG ResearchBoost Price TargetBuy$47.00 -> $56.00MediumView Rating Details
4/4/2017Robert W. BairdReiterated RatingOutperform$40.00MediumView Rating Details
4/3/2017WedbushReiterated RatingOutperform -> Outperform$30.00HighView Rating Details
11/3/2016Leerink SwannReiterated RatingBuy$23.00N/AView Rating Details
6/17/2016Ladenburg Thalmann Financial ServicesBoost Price TargetBuy$46.00 -> $52.00N/AView Rating Details
7/22/2015GabelliInitiated CoverageBuy$34.00N/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Paratek Pharmaceuticals (NASDAQ:PRTK)
Earnings by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)
Earnings History by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($1.20)($1.14)$0.02 millionViewListenView Earnings Details
3/2/2017Q4 2016($1.33)($1.17)$0.03 millionViewListenView Earnings Details
11/2/2016($1.38)($1.04)ViewN/AView Earnings Details
5/2/2016($1.25)($1.77)ViewN/AView Earnings Details
2/23/2016Q4($1.18)($1.20)ViewListenView Earnings Details
11/12/2015Q315($0.91)($1.33)ViewListenView Earnings Details
8/5/2015Q215($0.75)($0.94)$3.62 billionViewN/AView Earnings Details
4/2/2015Q1($2.16)($0.74)$0.13 million$4.00 millionViewN/AView Earnings Details
5/5/2014($0.18)($0.15)$0.42 millionViewN/AView Earnings Details
3/13/2014Q413($0.21)($0.29)$0.50 million$0.32 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.42)($0.56)ViewN/AView Earnings Details
11/12/2012Q312$0.06$0.25$8.37 million$10.44 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Paratek Pharmaceuticals (NASDAQ:PRTK)
2017 EPS Consensus Estimate: ($3.47)
2018 EPS Consensus Estimate: ($3.13)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.15)($1.15)($1.15)
Q2 20171($0.79)($0.79)($0.79)
Q3 20171($0.86)($0.86)($0.86)
Q4 20171($0.67)($0.67)($0.67)
Q1 20181($0.86)($0.86)($0.86)
Q2 20181($0.88)($0.88)($0.88)
Q3 20181($0.52)($0.52)($0.52)
Q4 20181($0.87)($0.87)($0.87)
(Data provided by Zacks Investment Research)

Dividends

Dividend History by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/14/2014special$1.336/4/20145/26/20146/3/2014
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Paratek Pharmaceuticals (NASDAQ:PRTK)
Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 76.06%
Insider Trades by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)
Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)
Insider Trades by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/6/2017Douglas W PaganCFOSell3,405$15.09$51,381.45View SEC Filing  
2/6/2017Evan LohCOOSell3,106$15.09$46,869.54View SEC Filing  
2/6/2017Michael BighamChairmanSell5,000$15.09$75,450.00View SEC Filing  
6/27/2016Fund Iv L.P. OmegaMajor ShareholderBuy461,538$13.00$5,999,994.00View SEC Filing  
6/23/2016Michael BighamCEOBuy20,000$13.45$269,000.00View SEC Filing  
12/11/2015Evan LohCMOBuy2,300$16.87$38,801.00View SEC Filing  
5/29/2015Hbm Healthcare Investments (CaMajor ShareholderSell20,580$30.75$632,835.00View SEC Filing  
12/13/2013Roumell Asset Management, Llcmajor shareholderSell1,470$3.54$5,203.80View SEC Filing  
12/11/2013Roumell Asset Management, Llcmajor shareholderSell10,490$3.55$37,239.50View SEC Filing  
12/6/2013Roumell Asset Management, Llcmajor shareholderSell8,710$3.54$30,833.40View SEC Filing  
12/4/2013Roumell Asset Management, Llcmajor shareholderSell7,120$3.50$24,920.00View SEC Filing  
11/20/2013Roumell Asset Management, Llcmajor shareholderSell10,040$3.57$35,842.80View SEC Filing  
11/12/2013Roumell Asset Management, Llcmajor shareholderSell7,190$3.53$25,380.70View SEC Filing  
11/7/2013Roumell Asset Management, Llcmajor shareholderSell4,960$3.61$17,905.60View SEC Filing  
10/30/2013Roumell Asset Management, LlcMajor ShareholderSell7,020$3.69$25,903.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Paratek Pharmaceuticals (NASDAQ:PRTK)
Latest Headlines for Paratek Pharmaceuticals (NASDAQ:PRTK)
Source:
DateHeadline
americanbankingnews.com logoParatek Pharmaceuticals Inc (PRTK) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - May 26 at 7:59 AM
globenewswire.com logoParatek Pharmaceuticals to Present New Data from Omadacycline Development Program at ASM Microbe 2017 - GlobeNewswire (press release)
www.globenewswire.com - May 24 at 7:39 PM
seekingalpha.com logoParatek Pharmaceuticals: The 1 Antibiotic Stock To Buy Now - Seeking Alpha
seekingalpha.com - May 22 at 6:29 PM
americanbankingnews.com logoParatek Pharmaceuticals Inc (PRTK) Research Coverage Started at Raymond James Financial, Inc.
www.americanbankingnews.com - May 18 at 10:56 PM
americanbankingnews.com logoAnalysts Offer Predictions for Paratek Pharmaceuticals Inc's FY2017 Earnings (PRTK)
www.americanbankingnews.com - May 12 at 12:33 PM
americanbankingnews.com logo$7.5 Million in Sales Expected for Paratek Pharmaceuticals Inc (PRTK) This Quarter
www.americanbankingnews.com - May 10 at 11:14 AM
americanbankingnews.com logo Analysts Expect Paratek Pharmaceuticals Inc (PRTK) Will Announce Earnings of -$1.08 Per Share
www.americanbankingnews.com - May 8 at 1:18 PM
finance.yahoo.com logoParatek Announces Completion of Enrollment for Oral-only Omadacycline Phase 3 Skin Study, Top-line Data Expected in Mid-July
finance.yahoo.com - May 8 at 11:56 AM
americanbankingnews.com logoWedbush Equities Analysts Boost Earnings Estimates for Paratek Pharmaceuticals Inc (PRTK)
www.americanbankingnews.com - May 8 at 8:21 AM
americanbankingnews.com logoParatek Pharmaceuticals Inc (PRTK) PT Set at $33.00 by Cantor Fitzgerald
www.americanbankingnews.com - May 7 at 8:02 AM
americanbankingnews.com logoAnalysts Set Expectations for Paratek Pharmaceuticals Inc's Q1 2018 Earnings (PRTK)
www.americanbankingnews.com - May 5 at 5:32 PM
americanbankingnews.com logoParatek Pharmaceuticals Inc (PRTK) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS
www.americanbankingnews.com - May 5 at 5:30 PM
finance.yahoo.com logoToday's Research Reports on Arrowhead Pharmaceuticals and Paratek Pharmaceuticals Post Earnings
finance.yahoo.com - May 5 at 8:29 AM
seekingalpha.com logoParatek Pharmaceuticals, Inc. (PRTK)
seekingalpha.com - May 5 at 12:34 AM
finance.yahoo.com logoParatek Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results and Provides Clinical Update
finance.yahoo.com - May 5 at 12:34 AM
finance.yahoo.com logoInvestor Network: Paratek Pharmaceuticals Inc to Host Earnings Call
finance.yahoo.com - May 5 at 12:34 AM
finance.yahoo.com logoParatek Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results and Provides Clinical Update - Yahoo Finance
finance.yahoo.com - May 4 at 7:32 PM
finance.yahoo.com logoHere's Why Paratek Pharmaceuticals Rose as Much as 16.1% Today
finance.yahoo.com - May 4 at 7:32 PM
globenewswire.com logoParatek Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results and Provides Clinical Update - GlobeNewswire (press release)
globenewswire.com - May 4 at 8:22 AM
marketbeat.com logoParatek reports 1Q loss
marketbeat.com - May 4 at 8:18 AM
americanbankingnews.com logoParatek Pharmaceuticals (PRTK) Receives Daily Media Sentiment Rating of 0.29
www.americanbankingnews.com - May 3 at 6:54 PM
americanbankingnews.com logoParatek Pharmaceuticals (PRTK) Earning Somewhat Favorable Press Coverage, Report Shows
www.americanbankingnews.com - April 30 at 9:44 AM
americanbankingnews.com logoParatek Pharmaceuticals Inc (PRTK) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - April 29 at 8:39 AM
americanbankingnews.com logoParatek Pharmaceuticals (PRTK) Getting Favorable Media Coverage, Analysis Shows
www.americanbankingnews.com - April 28 at 12:44 AM
finance.yahoo.com logoParatek Pharmaceuticals to Report First Quarter 2017 Financial Results and Provide Update on Clinical Progress on May 4, 2017
finance.yahoo.com - April 26 at 5:58 PM
finance.yahoo.com logoOmadacycline Concentrations Exceed Tigecycline Levels in Lungs and Epithelial Lining Fluid According to Pharmacokinetic/Pharmacodynamic (PK/PD) Data
finance.yahoo.com - April 25 at 8:30 AM
americanbankingnews.com logoParatek Pharmaceuticals (PRTK) Earns Daily Media Sentiment Score of 0.21
www.americanbankingnews.com - April 24 at 7:50 PM
streetinsider.com logoParatek Pharmaceuticals (PRTK) and Zai Lab Enter Pact for Omadacycline in China
www.streetinsider.com - April 24 at 7:04 PM
finance.yahoo.com logoParatek Pharmaceuticals and Zai Lab Announce Collaboration, Development and License Agreement for Omadacycline in China
finance.yahoo.com - April 24 at 7:04 PM
finance.yahoo.com logoNew Health Economics Studies Highlight the Potential for Paratek Pharmaceuticals’ Omadacycline to Provide Cost-Savings Compared to Standard of Care for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections
finance.yahoo.com - April 24 at 7:04 PM
finance.yahoo.com logoNew Microbiology Data from Paratek Pharmaceuticals Show Omadacycline Effective Against Most Common Skin Infections and Pathogens, Including MRSA
finance.yahoo.com - April 24 at 7:04 PM
americanbankingnews.com logoParatek Pharmaceuticals Inc (PRTK) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - April 24 at 2:08 PM
streetinsider.com logoParatek Pharmaceuticals (PRTK) Says New Microbiology Data Shows Omadacycline Effective Against Most Common ... - StreetInsider.com
www.streetinsider.com - April 24 at 2:03 PM
americanbankingnews.com logoParatek Pharmaceuticals (PRTK) Given Daily Media Impact Score of 0.31
www.americanbankingnews.com - April 21 at 11:20 PM
americanbankingnews.com logoParatek Pharmaceuticals Inc (PRTK) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 21 at 7:24 AM
americanbankingnews.com logoParatek Pharmaceuticals Inc (PRTK) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 21 at 12:11 AM
finance.yahoo.com logoParatek Pharmaceuticals to Present New Data from Omadacycline ... - Yahoo Finance
finance.yahoo.com - April 19 at 7:19 PM
zacks.com logoWhy Paratek Pharmaceuticals (PRTK) Could Be Positioned for a Surge?
www.zacks.com - April 19 at 9:46 AM
americanbankingnews.com logoParatek Pharmaceuticals (PRTK) Receiving Somewhat Favorable Media Coverage, Analysis Finds
www.americanbankingnews.com - April 18 at 9:34 PM
finance.yahoo.com logoParatek Pharmaceuticals to Present New Data from Omadacycline Development Program at ECCMID 2017
finance.yahoo.com - April 18 at 6:39 PM
americanbankingnews.com logo Brokerages Expect Paratek Pharmaceuticals Inc (PRTK) Will Post Earnings of -$1.20 Per Share
www.americanbankingnews.com - April 17 at 3:06 PM
americanbankingnews.com logoParatek Pharmaceuticals (PRTK) Getting Somewhat Negative Media Coverage, Report Shows
www.americanbankingnews.com - April 15 at 2:13 PM
americanbankingnews.com logoParatek Pharmaceuticals Inc (PRTK) Sees Large Increase in Short Interest
www.americanbankingnews.com - April 15 at 7:04 AM
americanbankingnews.com logoGabelli Comments on Paratek Pharmaceuticals Inc's FY2018 Earnings (PRTK)
www.americanbankingnews.com - April 7 at 7:21 PM
americanbankingnews.com logoParatek Pharmaceuticals Inc (PRTK) PT Set at $38.00 by Guggenheim
www.americanbankingnews.com - April 5 at 3:22 PM
americanbankingnews.com logoParatek Pharmaceuticals' (PRTK) Overweight Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - April 5 at 2:01 PM
americanbankingnews.com logoParatek Pharmaceuticals Inc (PRTK) to Post Q1 2017 Earnings of ($1.15) Per Share, Wedbush Forecasts
www.americanbankingnews.com - April 5 at 11:10 AM
americanbankingnews.com logoBTIG Research Reaffirms "Buy" Rating for Paratek Pharmaceuticals Inc (PRTK)
www.americanbankingnews.com - April 4 at 9:48 PM
americanbankingnews.com logoParatek Pharmaceuticals Inc (PRTK) Rating Reiterated by Robert W. Baird
www.americanbankingnews.com - April 4 at 9:48 PM
fool.com logoWhy Paratek Pharmaceuticals Inc Is Soaring
www.fool.com - April 4 at 12:47 PM

Social

Chart

Paratek Pharmaceuticals (PRTK) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff